Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR3 | P49682 | 19/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12464092 | 0.90 | CXCR3 (0.57) | CXCR3 | |
| SCHEMBL12464005 | 0.87 | CXCR3 (0.58) | CXCR3 | |
| SCHEMBL14264691 | 0.86 | CXCR3 (0.62) | CXCR3 | |
| SCHEMBL12463945 | 0.83 | CXCR3 (0.55) | CXCR3 | |
| SCHEMBL12829861 | 0.80 | CXCR3 (0.88) | CXCR3 | |
| SCHEMBL12830456 | 0.78 | CXCR3 (0.63) | CXCR3 | |
| SCHEMBL16152253 | 0.78 | CXCR3 (0.58) | CXCR3 | |
| SCHEMBL8437614 | 0.77 | CXCR3 (0.65) | CXCR3 | |
| SCHEMBL13291361 | 0.75 | CXCR3 (0.57) | CXCR3 | |
| SCHEMBL14264699 | 0.75 | CXCR3 (0.63) | CXCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170246168-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2017-08-31 | — | — | US | disclosed |
| US-20170246168-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2017-08-31 | — | — | US | disclosed |
| US-9649312-B2 | Compositions and methods of treatment of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2017-05-16 | — | — | US | disclosed |
| US-9649312-B2 | Compositions and methods of treatment of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160324858-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-20160324858-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION | 2016-11-10 | — | — | US | disclosed |
| US-20130190495-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130190495-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2013-07-25 | — | — | US | disclosed |
| US-8349853-B2 | Detection defect in gene expression of hedgehog gene; diagnosis of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349853-B2 | Detection defect in gene expression of hedgehog gene; diagnosis of cancer | MINERVA BIOTECHNOLOGIES CORPORATION (US) | 2013-01-08 | — | — | US | disclosed |
| EP-2340838-A1 | Compositions and Methods of Treatment of Cancer | Minerva Biotechnologies Corporation (US) | 2011-07-06 | — | — | EP | disclosed |
| EP-2329822-A1 | Compositions and methods of treatment of cancer | Minerva Biotechnologies Corporation (US) | 2011-06-08 | — | — | EP | disclosed |
| EP-1425016-B1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MINERVA BIOTECHNOLOGIES CORP (US) | 2010-06-02 | — | — | EP | disclosed |
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MINERVA BIOTECHNOLOGIES CORPORATION | 2008-03-13 | — | — | US | disclosed |
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MINERVA BIOTECHNOLOGIES CORPORATION | 2008-03-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160324858-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MUC1, TP53, BRCA1 | CXCR3 109/4885 |
| US-20080064680-A1 | Methods for Diagnosis and Treatment of Cancer | MUC1, CD44, TP53 | CXCR3 1257/4885 |
| US-20130190495-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MUC1, TP53, BRCA1 | CXCR3 109/4885 |
| US-20170246168-A1 | COMPOSITIONS AND METHODS OF TREATMENT OF CANCER | MUC1, TP53, BRCA1 | CXCR3 109/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.